Ophthalmology

Based on personal clinical experience, Arshad Khanani, MD, explains his current approach to treating wet age-related macular degeneration with anti-VEGF therapy, with special considerations for appropriate dosage and timing of injections, and describes how he assesses patient response to therapy.

Dr Arshad Khanani describes the role of anti-VEGF therapy for wet age-related macular degeneration and elaborates on factors that impact treatment selection and sequencing in a patient’s continuum of care.

Strategies that can be used to screen and confirm a diagnosis of age-related macular degeneration, as well as monitor patients to optimize care.

Arshad Khanani, MD, defines age-related macular degeneration as it relates to vision loss, highlighting the ways the condition may present in patients and its impact on quality of life.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

The cumulative incidence of disease among participants in the low-, medium-, and high-risk tertiles was 31.7%, 47.6%, and 59.8%, respectively.

SDOCT imaging shows that sickle cell patients with no clinical evidence of retinopathy have considerably lower central macular thickness when compared with healthy controls.

Some exposed newborns with negative PCR assays presented with fundus abnormalities.

Contrast suppression was substantially lower for patients with major depressive disorder.

The investigators found lower absolute T-MoCA scores in the NTG arm of the study when compared to the high tension glaucoma cohort.

Some fear repeated injections of anti-VEGF drugs might harm retinal nerve fiber layer, but a new study finds little evidence of such harm.

Patients with subjective vision changes should be referred for fundus examination.

Patients who underwent the therapy also had greater myopic shift compared to those that did not.

The launch of a My Retina Tracker dramatically increased testing rates, which could help lead to better clinical trials and therapies.

Investigators noted a higher prevalence of nuclear sclerotic cataracts in infected patients versus uninfected patients.

Noncompliance among younger patients and lack of education are issues that should continually be addressed by care teams.

In a Q&A, 2 ophthalmologists provide an overview and offer some perspective on the risks and heritability associated with glaucoma.

The number of individuals suffering from vision impairment expected to rise to 895 million by 2050.

No approved treatment for leber hereditary optic neuropathy is currently available in the United States.

The company plans to submit the data to the FDA and EMA for consideration of the injectable bispecific antibody's regulatory approval for the treatment of both conditions.

This approval was granted to generic pharmaceutical company Akorn Operating Company, LLC.

Hydroxyurea therapy was associated with decreased rates of retinal thinning and could be a protective factor.

Eysuvis 0.25% is the first and only approved prescription therapy for short-term treatment of signs and symptoms related to dry eye disease.

Low and moderate dosing shows the most potential in preventing AMD for patients with diabetes.

Patients treated with the bispecific antibody at fixed intervals of 16 weeks achieved visual acuity outcomes comparable to 8-week interval treatment of aflibercept.

The researchers unexpectedly found sustained visual improvement in both eyes, despite only 1 eye being treated with AAV.

Primate model studies show the procedure can be done safely and without losing eye function. Which patients may benefit first?

Primary care physicians should be aware of which patients are at high risk for developing glaucoma.

Up to 83% of evaluated individuals indicated that their ocular symptoms began within two weeks of their other COVID-19 symptoms

A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.